Formulations and Treatments for Well-Being

1. A formulation for well-being in humans including:

extracts from the herbal varieties:

Polygonum multiflorum,

Panax quinquefolium,

Gingko biloba, and

Equisetum arvense;

beta sitosterol

methyl sulfonyl methane;

soy isoflavones;

levo-arginine;

inositol;

niacin;

pantothenic acid or salts thereof;

alpha-tocopherol;

biotin;

pyridoxine hydrochloride

zinc (or amino acid chelate thereof); and

colostrum.

2. A formulation for well-being in humans including a 5-alpha reductase production inhibitor and methylsulfonylmethane.

3. A formulation for well-being according to claim 2, wherein the 5-alpha reductase production inhibitor is selected from one or more phytosterols.

4. A formulation for well-being according to claim 3, wherein the phytosterols are selected as equivalents to beta-sitosterol.

5. A formulation for well-being according to any one of claims 2 to 4, wherein the 5-alpha reductase production may inhibitor includes extract from Serenoa repens

6. A formulation for well-being according to any one of claims 2 to 4, wherein the 5-alpha reductase production may inhibitor includes extract from Saw palmetto.

7. A formulation for well-being according to any one of claims 2 to 6 and including herbal extracts according to claim 1.

8. A formulation for well-being according to claim 1 or claim 7, wherein the herbal extracts include Pygeum repens.

9. A formulation for well-being according to claim 1, claim 7 or claim 8, wherein the formulation includes thiamine.

10. A formulation for well-being according to claim 1 or any one of claims 7 to 9, wherein the formulation includes riboflavin.

11. A formulation for well-being in humans including:

a 5-alpha reductase production inhibitor;

methylsulfonylmethane; and

extract from the herbal variety Polygonum multiflorum.

12. A formulation for well-being in humans including:

a 5-alpha reductase production inhibitor;

methylsulfonylmethane;

extract from the herbal variety Polygonum multiflorum; and

colostrum.

13. A formulation for well-being in humans including:

a 5-alpha reductase production inhibitor;

methylsulfonylmethane;

extract from the herbal variety Polygonum multiflorum; and

levo-arginine.

14. A formulation for well-being in humans including:

a 5-alpha reductase production inhibitor;

methylsulfonylmethane;

extract from the herbal variety Polygonum multiflorum;

levo-arginine and

colostrum.

15. A formulation for well-being in humans including:

a 5-alpha reductase production inhibitor;

methylsulfonylmethane;

extract from the herbal variety Polygonum multiflorum;

levo-arginine;

colostrum; and

Gingko biloba.

16. A formulation for well-being in humans including:

extract from the herbal variety Polygonum multiflorum;

a 5-alpha reductase production inhibitor;

methylsulfonylmethane; and

colostrum.

17. A formulation for well-being according to claim 16 and including zinc amino acid chelate.

18. A formulation for well-being according to claim 16 or claim 17 and including Gingko biloba.

19. A formulation for well-being according to any one of claims 16 to 18, wherein the formulation includes any one or more extracts from the herbal varieties:

Polygonum multiflorum;

Gingko biloba;

Equisetum arvense;

Panax quinquefolium.

20. A formulation for well-being according to any one of claims 16 to 19, wherein the formulation includes any one or more of the following components:

one or more soy isoflavones;

levo-arginine;

inositol;

niacin;

biotin;

calcium pantothenate;

dextro-alpha-tocopherol;

pyridoxine hydrochloride.

21. A formulation for well-being according to any one of claims 1, 12, 14 to 20, wherein the colostrum is selected efficacy in ameliorating the reduction of growth hormone (“GH”) and/or insulin-like growth factor 1 (“IGF-1”) with ageing.

22. A formulation for well-being according to any one of claims 1, 12, 14 to 20, wherein the colostrum is bovine colostrum.

23. A formulation for well-being in humans including, in a dosage in the range of 3 g to 8 g:

phytosterols in the range of 200 mg to 2500 mg;

the quantitative equivalent of Polygonum multiflorum root 4:1 in 70% EW in the range of 600 mg to 2600 mg;

methylsulfonylmethane in the range of 500 mg to 2000 mg; and

bovine colostrum in the range of 500 mg to 2000 mg.

24. A formulation for well-being according to claim 23, wherein the formulation further includes the quantitative equivalent of Gingko biloba leaf extract 50:1 in 70% EW in the range of 50 mg to 1000 mg.

25. A formulation for well-being according to claim 23 or claim 24, wherein the formulation further includes the quantitative equivalent of zinc amino acid chelate 20% in the range of 10 mg to 40 mg.

26. A formulation for well-being according to any one of claims 23 to 25, wherein the formulation includes any one or more of the following components:

arginine in the range of 120 mg to 500 mg;

biotin in the range of 0.7 mg to 5 mg;

nicotinic acid in the range of 5 mg to 30 mg;

calcium pantothenate in the range of 10 mg to 400 mg;

pyridoxine hydrochloride in the range of 10 mg to 400 mg;

d-α-tocopherol acetate in the range of 200 IU to 800 IU; and

colloidal anhydrous silica in the range of 60 mg to 500 mg.

27. A formulation for well-being according to any one of claims 23 to 26, wherein the formulation also includes any one or more of the following components:

the quantitative equivalent of Glycine Max (soy) seed 65:1 in 75% EW in the range of 80 mg to 3250 mg;

the quantitative equivalent of Panax quinquefolium root extract 3:1 in 15% EW in the range of 50 mg to 1000 mg;

the quantitative equivalent of Equisetum arvense herb extract 4:1 in 100% water in the range of 50 mg to 1000 mg;

inositol in the range of 70 mg to 300 mg;

28. A formulation for well-being according to claim 27, wherein the phytosterols are in the range of 200 mg to 2500 mg.

29. A formulation for well-being according to claim 27, wherein the phytosterols are in the range of 200 mg to 1000 mg.

30. A formulation for well being according to claim 27 when dependant on any one of claims 24 to 26, wherein the Gingko biloba extract is in the range of 50 mg to 1000 mg.

31. A formulation for well being according to claim 27 when dependant on any one of claims 24 to 26, wherein the Gingko biloba extract is in the range of 50 mg to 500 mg.

32. A formulation for well being according to claim 27, wherein the Panax quinquefolium root extract is in the range of 50 mg to 1000 mg.

33. A formulation for well being according to claim 27, wherein the Panax quinquefolium root extract is in the range of 50 mg to 500 mg.

34. A formulation for well being according to claim 27, wherein the Equisetum arvense herb extract is in the range of 50 mg to 1000 mg.

35. A formulation for well being according to claim 27, wherein the Equisetum arvense herb extract is in the range of 50 mg to 500 mg.

36. A formulation for well being according to claim 27, wherein the bovine colostrum is in the range of 50 mg to 2000 mg.

37. A formulation for well being according to claim 27, wherein the bovine colostrum is in the range of 500 mg to 1000 mg.

38. A formulation for well being according to claim 26, wherein the biotin is in the range of 0.7 mg to 3 mg.

39. A formulation for well being according to claim 26, wherein the pyridoxine hydrochloride is in the range of 100 mg to 400 mg.

40. A formulation for well-being according to any one of claims 27 to 39 and including Trusil natural lemon/lime in the range of 6 to 26 mg

41. A formulation for well-being according to any one of claims 27 to 39 and including fructose in the range of 125 mg to 500 mg.

42. A formulation for well-being of a human patient including:

a biological sulfur nutritional supplement for providing biologically active sulfur;

one or more dihydrotestosterone blocking components for inhibiting the binding of dihydrotestosterone to receptor sites and/or inhibits the action of 5-alpha-reductase in converting testosterone to dihydrotestosterone;

one or more capillary blood-flow promoters for promoting capillary blood flow;

a growth factor component for promoting cell growth by ameliorating the reduction of growth hormone (“GH”) and/or insulin-like growth factor 1 (“IGF-1”) with ageing;

an amino acid component having at least some of all of the essential amino acids for human metabolism; and

a mineral component for introducing at least the minerals silicon and zinc into the patient.

43. A formulation for well-being according to claim 42, wherein the formulation includes a vitamin component having at least some vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B8, vitamin Bx, and vitamin E.

44. A formulation for well-being according to claim 42 or 43, wherein the components are selected from the phytosterols, Polygonum multiflorum root (fo-ti), Glycine Max (soy) seed, Gingko biloba leaf, Panax quinquefolium root, Equisetum arvense, inositol, methylsulfonylmethane, bovine colostrum, arginine, biotin, nicotinic acid, calcium pantothenate, pyridoxine hydrochloride, d-α-tocopherol acetate, Trusil natural lemon/lime or a flavouring agent equivalent thereto, fructose or a sweetening agent equivalent thereto, colloidal anhydrous silica and zinc amino acid chelate to male up a dosage in the range of 3 g to 8 g according to claim 23.

46. A formulation for well-being according to any one of claims 42 to 44, wherein the amino acid component includes isoflavones.

47. A formulation for well-being according to any one of claims 42 to 44, wherein the amino acid component includes phytosterols.

48. A formulation for well-being according to any one of claims 42 to 44, wherein the amino acid component includes a phytoestrogen.

49. A formulation for well-being according to any one of claims 42 to 44, wherein the amino acid component includes Genistein.

50. A formulation for well-being according to any one of claims 42 to 44, wherein the amino acid component includes Daidzien.

51. A medicinal formulation for well-being in humans including:

extracts from the herbal varieties:

Polygonum multiflorum;

Gingko biloba;

Equisetum arvense;

Panax quinquefolium;

methylsulfonylmethane;

levo-arginine;

a 5-alpha reductase production inhibitor;

one or more soy isoflavones;

inositol;

niacin;

biotin;

calcium pantothenate;

dextro-alpha-tocopherol;

pyridoxine hydrochloride;

zinc amino acid chelate; and

colostrum.

52. A formulation for well-being of a patient including, in a dosage in the range of 3 g to 8 g:

phytosterols in the range of 200 mg to 2500 mg;

the quantitative equivalent of Polygonum multiflorum root 4:1 in 70% EW in the range of 600 mg to 2600 mg;

the quantitative equivalent of Glycine Max (soy) seed 65:1 in 75% EW in the range of 800 mg to 3250 mg;

the quantitative equivalent of Gingko biloba leaf extract 50:1 in 70% EW in the range of 50 mg to 1000 mg;

the quantitative equivalent of Panax quinquefolium root extract 3:1 in 15% EW in the range of 50 mg to 1000 mg;

the quantitative equivalent of Equisetum arvense herb extract 4:1 in 100% water in the range of 50 mg to 1000 mg;

inositol in the range of 70 mg to 300 mg;

methylsulfonylmethane in the range of 500 mg to 2000 mg;

bovine colostrum in the range of 500 mg to 2000 mg;

arginine in the range of 120 mg to 500 mg;

biotin in the range of 0.7 mg to 5 mg;

nicotinic acid in the range of 5 mg to 30 mg;

calcium pantothenate in the range of 100 mg to 400 mg;

pyridoxine hydrochloride in the range of 10 mg to 400 mg;

d-α-tocopherol acetate in the range of 200 IU to 800 IU;

Trusil natural lemon/lime in the range of 6 to 26 mg or a flavouring agent equivalent thereto;

fructose in the range of 125 mg to 500 mg or a sweetening agent equivalent thereto;

colloidal anhydrous silica in the range of 60 mg to 500 mg; and

the quantitative equivalent of zinc amino acid chelate 20% in the range of 10 mg to 40 mg.

53. A method of enhancing the well-being of a human patient including the steps of: preparing a predetermined quantity of a formulation consisting of: extracts from the herbal varieties Polygonum multiflorum, Panax quinquefolium, Gingko biloba, and Equisetum arvense; beta sitosterol; methyl sulfonyl methane; soy isoflavones; levo-arginine; inositol; niacin; pantothenic acid or salts thereof; alpha-tocopherol; biotin; pyridoxine hydrochloride; zinc (or amino acid chelate thereof); and colostrum and

preparing the quantity for ingestion by the human patient.

54. A method of enhancing the well-being of a human patient including the steps of: preparing a predetermined quantity of a formulation consisting of: a biological sulfur nutritional supplement for providing biologically active sulfur; one or more capillary blood-flow promoters for promoting capillary blood flow; a growth factor component for promoting cell growth by ameliorating the reduction of growth hormone (“GH”) and/or insulin-like growth factor 1 (“IGF-1”) with ageing; an amino acid component having at least some of all of the essential amino acids for human metabolism; a mineral component for introducing at least the minerals silicon and zinc into the patient; and a vitamin component having at least some vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B8, vitamin Bx, and vitamin E; and

preparing the predetermined quantity for ingestion by the human patient.